Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
BACKGROUND: Rift Valley Fever (RVF) is a viral zoonosis that historically affects livestock production and human health in sub-Saharan Africa, though epizootics have also occurred in the Arabian Peninsula. Whilst an effective live-attenuated vaccine is available for livestock, there is currently no...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2013
|
| _version_ | 1797067051840307200 |
|---|---|
| author | Warimwe, G Lorenzo, G Lopez-Gil, E Reyes-Sandoval, A Cottingham, M Spencer, A Collins, K Dicks, M Milicic, A Lall, A Furze, J Turner, A Hill, A Brun, A Gilbert, S |
| author_facet | Warimwe, G Lorenzo, G Lopez-Gil, E Reyes-Sandoval, A Cottingham, M Spencer, A Collins, K Dicks, M Milicic, A Lall, A Furze, J Turner, A Hill, A Brun, A Gilbert, S |
| author_sort | Warimwe, G |
| collection | OXFORD |
| description | BACKGROUND: Rift Valley Fever (RVF) is a viral zoonosis that historically affects livestock production and human health in sub-Saharan Africa, though epizootics have also occurred in the Arabian Peninsula. Whilst an effective live-attenuated vaccine is available for livestock, there is currently no licensed human RVF vaccine. Replication-deficient chimpanzee adenovirus (ChAd) vectors are an ideal platform for development of a human RVF vaccine, given the low prevalence of neutralizing antibodies against them in the human population, and their excellent safety and immunogenicity profile in human clinical trials of vaccines against a wide range of pathogens. METHODS: Here, in BALB/c mice, we evaluated the immunogenicity and efficacy of a replication-deficient chimpanzee adenovirus vector, ChAdOx1, encoding the RVF virus envelope glycoproteins, Gn and Gc, which are targets of virus neutralizing antibodies. The ChAdOx1-GnGc vaccine was assessed in comparison to a replication-deficient human adenovirus type 5 vector encoding Gn and Gc (HAdV5-GnGc), a strategy previously shown to confer protective immunity against RVF in mice. RESULTS: A single immunization with either of the vaccines conferred protection against RVF virus challenge eight weeks post-immunization. Both vaccines elicited RVF virus neutralizing antibody and a robust CD8+ T cell response. CONCLUSIONS: Together the results support further development of RVF vaccines based on replication-deficient adenovirus vectors, with ChAdOx1-GnGc being a potential candidate for use in future human clinical trials. |
| first_indexed | 2024-03-06T21:50:46Z |
| format | Journal article |
| id | oxford-uuid:4b2be378-7381-4c19-ac22-a5933abf63ba |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:50:46Z |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:4b2be378-7381-4c19-ac22-a5933abf63ba2022-03-26T15:42:02ZImmunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4b2be378-7381-4c19-ac22-a5933abf63baEnglishSymplectic Elements at OxfordBioMed Central2013Warimwe, GLorenzo, GLopez-Gil, EReyes-Sandoval, ACottingham, MSpencer, ACollins, KDicks, MMilicic, ALall, AFurze, JTurner, AHill, ABrun, AGilbert, SBACKGROUND: Rift Valley Fever (RVF) is a viral zoonosis that historically affects livestock production and human health in sub-Saharan Africa, though epizootics have also occurred in the Arabian Peninsula. Whilst an effective live-attenuated vaccine is available for livestock, there is currently no licensed human RVF vaccine. Replication-deficient chimpanzee adenovirus (ChAd) vectors are an ideal platform for development of a human RVF vaccine, given the low prevalence of neutralizing antibodies against them in the human population, and their excellent safety and immunogenicity profile in human clinical trials of vaccines against a wide range of pathogens. METHODS: Here, in BALB/c mice, we evaluated the immunogenicity and efficacy of a replication-deficient chimpanzee adenovirus vector, ChAdOx1, encoding the RVF virus envelope glycoproteins, Gn and Gc, which are targets of virus neutralizing antibodies. The ChAdOx1-GnGc vaccine was assessed in comparison to a replication-deficient human adenovirus type 5 vector encoding Gn and Gc (HAdV5-GnGc), a strategy previously shown to confer protective immunity against RVF in mice. RESULTS: A single immunization with either of the vaccines conferred protection against RVF virus challenge eight weeks post-immunization. Both vaccines elicited RVF virus neutralizing antibody and a robust CD8+ T cell response. CONCLUSIONS: Together the results support further development of RVF vaccines based on replication-deficient adenovirus vectors, with ChAdOx1-GnGc being a potential candidate for use in future human clinical trials. |
| spellingShingle | Warimwe, G Lorenzo, G Lopez-Gil, E Reyes-Sandoval, A Cottingham, M Spencer, A Collins, K Dicks, M Milicic, A Lall, A Furze, J Turner, A Hill, A Brun, A Gilbert, S Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. |
| title | Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. |
| title_full | Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. |
| title_fullStr | Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. |
| title_full_unstemmed | Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. |
| title_short | Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice. |
| title_sort | immunogenicity and efficacy of a chimpanzee adenovirus vectored rift valley fever vaccine in mice |
| work_keys_str_mv | AT warimweg immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT lorenzog immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT lopezgile immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT reyessandovala immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT cottinghamm immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT spencera immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT collinsk immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT dicksm immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT milicica immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT lalla immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT furzej immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT turnera immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT hilla immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT bruna immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice AT gilberts immunogenicityandefficacyofachimpanzeeadenovirusvectoredriftvalleyfevervaccineinmice |